MORGAN STANLEY PLC/CALL/AMGEN/440/0.1/20.09.24 | Delayed Börse Stuttgart 10:26:37 30/05/2024 pm IST | ||
| 0.127 EUR | +0.79% |
|
| Current month | +33.68% | ||
| 1 month | +33.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 30/24/30 | 0.127 | +0.79% |
| 29/24/29 | 0.126 | -5.26% |
| 28/24/28 | 0.133 | +9.92% |
| 27/24/27 | 0.121 | -7.63% |
| 24/24/24 | 0.131 | +15.93% |
Delayed Quote Börse Stuttgart
Last update May 30, 2024 at 10:26 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | ME22QB |
| ISIN | DE000ME22QB0 |
| Date issued | 13/10/2023 |
| Strike | 440 $ |
| Maturity | 20/09/2024 (113 Days) |
| Parity | 10 : 1 |
| Emission price | 0.14 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.22 € |
|---|---|
| Lowest since issue | 0.078 € |
| Spread | 0.024 € |
| Spread % | 16.11% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
301
USD
Average target price
316.3
USD
Spread / Average Target
+5.07%
- Stock Market
- Warrants
- Warrant
